These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 39256832)
1. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs). Zhang Z; Xiao Y; Zhao S; Liu J; Zeng J; Xiao F; Liao B; Shan X; Zhu H; Guo H J Transl Med; 2024 Sep; 22(1):833. PubMed ID: 39256832 [TBL] [Abstract][Full Text] [Related]
2. Integrated bioinformatics analysis and experimental validation on malignant progression and immune cell infiltration of LTBP2 in gliomas. Gao L; Zhang R; Zhang W; Lan Y; Li X; Cai Q; Liu J BMC Cancer; 2024 Oct; 24(1):1252. PubMed ID: 39390437 [TBL] [Abstract][Full Text] [Related]
3. Ma W; Zhang K; Bao Z; Jiang T; Zhang Y Front Immunol; 2021; 12():659659. PubMed ID: 33936093 [TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment. Zhu L; Yuan F; Wang X; Zhu R; Guo W Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883 [TBL] [Abstract][Full Text] [Related]
5. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy. Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J Front Immunol; 2023; 14():1338244. PubMed ID: 38250074 [TBL] [Abstract][Full Text] [Related]
6. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421 [TBL] [Abstract][Full Text] [Related]
7. Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma. Zhong WJ; Zhang LZ; Yue F; Yuan L; Zhang Q; Li X; Lin L Cancer Biomark; 2024; 40(3-4):297-317. PubMed ID: 39213054 [TBL] [Abstract][Full Text] [Related]
8. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847 [TBL] [Abstract][Full Text] [Related]
9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
10. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma. Hao YP; Wang WY; Qiao Q; Li G Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884 [TBL] [Abstract][Full Text] [Related]
11. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
12. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
13. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
14. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma. Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420 [TBL] [Abstract][Full Text] [Related]
15. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma(LGG). Liu H; Wang J; Luo T; Zhen Z; Liu L; Zheng Y; Zhang C; Hu X Front Endocrinol (Lausanne); 2022; 13():1106120. PubMed ID: 36714574 [TBL] [Abstract][Full Text] [Related]
16. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma. Wang LC; Cui WY; Zhang Z; Tan ZL; Lv QL; Chen SH; Shen XL Brain Res Bull; 2021 Oct; 175():26-36. PubMed ID: 34280481 [TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
18. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma. Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834 [TBL] [Abstract][Full Text] [Related]
19. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
20. LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification. Zhou Y; Xiao D; Jiang X J Transl Med; 2022 Jul; 20(1):335. PubMed ID: 35879775 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]